EASL 2026 Data Disclosure: HepaThera's HT-101 + HT-102 Regimen Achieves 50% HBsAg Clearance Rate at 24 Weeks Post-Treatment Discontinuation
Recently, HepaThera presented the latest clinical study data for the HT-101 + HT-102 combination therapy in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) 2026 Annual Congress. Results demonstrated that the dual-mechanism combination regimen of HT-101 and HT-102 achieved rapid and profound reduction of hepatitis B surface antigen (HBsAg) in CHB patients, with sustained HBsAg clearance maintained following treatment discontinuation.
High rate and sustained HBsAg loss achieved with HT-101 plus HT-102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study
-
Following 24 weeks of treatment, the combination regimen achieved a mean HBsAg reduction of 4.2–4.6 log₁₀ IU/mL, with a clearance rate of 90%.
-
At 24 weeks post-treatment discontinuation, HBsAg levels remained reduced by 3.2–4.2 log₁₀ IU/mL, with a sustained clearance rate of 50%.
-
The combination therapy demonstrated favorable safety and tolerability profiles. Treatment-emergent adverse events were Grade 1–2 in severity; no drug-related serious adverse events (SAEs) were observed.
Statement by Dr. Wu Kai, Chief Executive Officer, HepaThera
"The latest clinical data confirm that the HT-101 + HT-102 dual-mechanism regimen delivers leading efficacy and a favorable safety profile, with the added advantage of once-every-4-weeks dosing, making it a premium therapeutic option for functional cure of chronic hepatitis B. The Company will accelerate clinical development at full speed, striving for the earliest possible regulatory approval and market launch, to bring the optimal choice for functional cure to chronic hepatitis B patients worldwide."
Founded in May 2021, HepaThera Biopharmaceutical Co., Ltd. is a biotechnology company dedicated to developing innovative therapeutics for liver diseases. The Company's core pipeline for functional cure of hepatitis B—HT-101 (GalNAc-conjugated siRNA) and HT-102 (fully human monoclonal antibody)—has both advanced to Phase II clinical stage and received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA). The Company is also actively expanding into broader liver disease markets, including NASH and liver cancer, with strategic focus on cutting-edge technologies such as RNA interference, antibody-drug conjugates, and cell therapy. HepaThera is committed to building a comprehensive liver disease innovative drug pipeline covering the full spectrum of "antiviral—antifibrotic—antitumor" therapies, with the goal of becoming a platform enterprise with significant influence in the liver disease therapeutic space.
END
